Budigalimab

Budigalimab (ABBV-181) is an investigational agent whose form is not stated in the registry developed by AbbVie. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 5 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)) and NCT06236438 (Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)), in hepatocellular carcinoma, non-small-cell lung cancer and bladder & urothelial cancer. The largest, NCT06236438, plans to enrol 840 participants with primary completion expected 2031-10. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.